Maze Therapeutics, Inc. (MAZE)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	167.50M
Net Income (ttm)	-18.27M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About MAZE

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our C...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 121
• Stock Exchange: NASDAQ
• Ticker Symbol: MAZE
• Website: https://mazetx.com/

Financial Performance

Financial numbers in USD